Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13114892 | 0.85 | MAPT (0.67) | MAPTMEN1KMT2ASIRT6ALDH1A1 | |
| SCHEMBL4399969 | 0.83 | MAPT (0.70) | MAPTMEN1KMT2ASIRT6ALDH1A1 | |
| SCHEMBL25169935 | 0.83 | MAPT (0.62) | MAPTMEN1KMT2ASIRT6ALDH1A1 | |
| SCHEMBL27832 | 0.82 | SIRT6 (0.59) | MAPTMEN1KMT2ASIRT6ALDH1A1 | |
| SCHEMBL3440274 | 0.82 | MAPT (0.59) | MAPTMEN1KMT2ASIRT6ALDH1A1 | |
| SCHEMBL15896472 | 0.81 | MAPT (0.72) | MAPTMEN1KMT2ASIRT6ALDH1A1 | |
| SCHEMBL29772076 | 0.80 | MAPT (0.55) | MAPTMEN1KMT2ASIRT6ALDH1A1 | |
| SCHEMBL29104 | 0.80 | MAPT (0.56) | MAPTMEN1KMT2ASIRT6ALDH1A1 | |
| SCHEMBL25189631 | 0.80 | MEN1 (0.60) | MAPTMEN1KMT2ASIRT6ALDH1A1 | |
| SCHEMBL25845505 | 0.80 | GFER (0.55) | MAPTMEN1KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | BRD9, BRD1, BRWD1 | MAPT 1277/4885MEN1 1407/4885KMT2A 1429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.